An Assessment of Clinical Continuous Glucose Monitoring Targets for Older and High-Risk People Living with Type 1 Diabetes

Diabetes Technol Ther. 2023 Feb;25(2):108-115. doi: 10.1089/dia.2022.0350. Epub 2022 Dec 13.

Abstract

Aim: To assess relationships between continuous glucose monitoring (CGM) time in range (TIR), 70-180 mg/dL, time below range (TBR), <70 mg/dL, time above range (TAR), >180 mg/dL, and glucose coefficient of variation (CV) in relation to currently recommended clinical CGM targets for older people, which recommend reduced TIR and TBR targets relative to the general type 1 diabetes population. Methods: We conducted a post hoc analysis using the JDRF Australia Adult Hybrid Closed Loop trial database examining correlations in 120 adults with type 1 diabetes of 3 weeks masked CGM (Guardian Sensor 3; Medtronic) metrics (n = 61 on multiple daily injections, 59 on non-CGM augmented pumps) using manual insulin dosing at baseline and at 26-weeks, with 50% randomized to automated insulin dosing (AID). Results: Correlations between baseline TIR and TAR were strong (r = -0.966; P < 0.0001), weak for TBR (r = 0.363; P < 0.0001), and glucose CV (r = 0.037; P = 0.687) while moderate between CV and TBR (r = 0.726; P < 0.0001). Associations were similar for participants aged >60 years (n = 15) versus younger subjects. Correlations of changes in (Δ) TIR with ΔTAR over 26 weeks were strong (r = -0.945; P < 0.001) and correlations for ΔTBR were weak (r = 0.025; P = 0.802). ΔCV did not significantly correlate with ΔTAR (r = -0.064; P = 0.526) but did with ΔTBR (r = 0.770; P = <0.001). Conclusions: Changes in TIR are not associated with changes in TBR. Thus, we recommend that for older AID users whilst TBR targets should be prioritized to reduce hypoglycemia-related risk, TBR should be addressed independently of TIR. Clinical Trial Registratrion number: (ACTRN12617000520336).

Keywords: Continuous glucose monitoring; Elderly; Glucose target ranges; Hypoglycemia; Type 1 diabetes.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Diabetes Mellitus, Type 1* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Insulin / therapeutic use

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin